Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00492206 · ClinicalTrials.gov registry record · Phase 2
Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC
A Phase 2 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00492206 is a Phase 2 study that has completed, run by University of Pittsburgh. The registered enrollment target is 40 participants.
The verdict
NCT00492206, a Phase 2 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is an open label, phase II study in which cetuximab with concurrent thoracic radiotherapy followed by consolidation chemotherapy with paclitaxel/carboplatin/cetuximab will be administered to subjects with locally advanced NSCLC.
Interventions
- DRUG Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-06 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00492206
The ClinicalTrials.gov registry entry for NCT00492206 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cetuximab is the first listed.
NCT00492206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00492206 about?
NCT00492206 is a clinical study titled "Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC". This is an open label, phase II study in which cetuximab with concurrent thoracic radiotherapy followed by consolidation chemotherapy with paclitaxel/carboplatin/cetuximab will be administered to subjects with locally advanced NSCLC.
What is the current status of trial NCT00492206?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2006-06. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00492206?
The interventions under investigation include: Cetuximab (DRUG).
Who is sponsoring clinical trial NCT00492206?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.